knowledge -WSS

knowledge

author：knowledge 2025-08-12 09:12:36 - browse：1

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The battle over 'scope creep' and who gets to be called 'doctor'

hotspot

focus

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

UHS says company favors patients whose insurance pays more

Merck drug for rare lung condition set for approval in U.S.

Covid vaccine financial winners and losers, from Pfizer to Novavax

Readout Newsletter: Merck, Vertex, and Viking updates

There's no autism epidemic. It's an autism diagnosis epidemic

focus

knowledge

focus

Hollywood unions extend contract negotiations for actors

Senate panel puts off hardest PBM reforms for another day

In age of alternative facts, a scholarly course on calling out crap

Rise in cancer among younger people worries and puzzles doctors

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: mifepristone case, GLP

The high cost of giving birth even with insurance

The Readout: Lenmeldy, GLP

hotspot

Supreme Court mifepristone arguments center on docs' right to sue

Abortion pill case raises question: who can sue the FDA?

CDC Director Mandy Cohen on transparency, trust, and health

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Study says nonprofit hospitals fall short in charity care spending

Merck drug for rare lung condition set for approval in U.S.

hotspot

knowledge

focus

knowledge